ImCheck HP

Exploring uncharted territories in immunomodulation
Butyrophilins & Gamma-delta T cells

ImCheck Therapeutics is driving innovation in immune system modulation based on our unique know-how in the butyrophilin (BTN) and BTN-like (BTNL) superfamily of checkpoint molecules. We are designing the next generation of immunotherapeutic antibodies for the treatment of cancer, infectious disease, and autoimmune disease.

Latest news


ImCheck Provides Updated ICT01 and Pembrolizumab Combination Data from the Phase I/IIa EVICTION Trial at AACR Annual Meeting 2022
Science & Medicine 
Read more
ImCheck Announces First Patients Dosed in Phase II of EVICTION Trial for ICT01
Science & Medicine 
Read more
For the third year in a row, ImCheck has been awarded by the French Tech as one of the top 120 French start-ups/scale-ups and among 7 French biotech developing innovative therapies
Leadership & Corporate 
Read more

2nd Tumor Myeloid-Directed Therapies Summit

From  Jun 14, 2022  to  Jun 16, 2022 

Read more

Congrès de l'Association Française d'Histotechnologie

From  Jun 16, 2022  to  Jun 17, 2022 

Read more

Gamma Delta T Therapies Summit

From  Jul 26, 2022  to  Jul 28, 2022 

Read more

STAY IN TOUCH WITH OUR LATEST NEWS

Subscribe to receive our press releases and related news